Joe Duarte

Dr. Joe Duarte is Chief Investment Strategist and Editor of Profit Catalyst Alert.  He has been a professional investor and independent analyst since 1990.  He is a former Registered Investment Advisor and author of the Bestselling "Options Trading for Dummies," now in its 4th edition and several other books including "Market Timing for Dummies" and "Successful Biotech Investing". Although Joe's favorite areas of the market are technology and healthcare, he is a versatile investor who enjoys finding that hidden gem stock before the crowd, no matter what the sector. He is an original CNBC Market Maven, and is visible regularly on Stockcharts.TV. He has published articles on Marketwatch.com and has been widely quoted in the major media including The Wall Street Journal and Barron’s magazine.  

Analyst Articles

[from today’s issue of Smart Tech Investor]Cambrex Corp. (CBM) manufactures active pharmaceutical ingredients for brand name and generic drugs that treat pain management, cardiovascular, central nervous system, endocrine, gastrointestinal, skin, respiratory and urinary conditions. The company specializes in all areas of development and manufacturing from the transition from research and… Read More

A picture is worth a thousand words. And, believe it or not, the odds of a biotech rally may be on the rise. We’ll note right here and now, that it is quite possible that we’re wrong given the potential for nasty earnings surprises or any other external events that… Read More

A picture is worth a thousand words. And, believe it or not, the odds of a biotech rally may be on the rise. We’ll note right here and now, that it is quite possible that we’re wrong given the potential for nasty earnings surprises or any other external events that… Read More

[from the Portfolio Update in today’s issue of Smart Tech Investor]I am adding Dyax Corp. (DYAX) to the STI Medical Profits Portfolio because it is very close to having a real shot for FDA approval for a drug (DX-2390) that treats  Hereditary Angioedema, a genetic disorder that occurs in… Read More

[from the Portfolio Update in today’s issue of Smart Tech Investor]I am adding Dyax Corp. (DYAX) to the STI Medical Profits Portfolio because it is very close to having a real shot for FDA approval for a drug (DX-2390) that treats  Hereditary Angioedema, a genetic disorder that occurs in… Read More

In this issue:The Big Picture: Biotech Sector Nears Major Decision PointIn Depth: New EBIS Pick – DYAX Corp (DYAX) – High Risk, High PotentialEBIS Portfolio Alerts: Alert: EBIS Portfolio Pricing Updates News Update: New FDA Commissioner Nominee Could Foster New Climate at AgencyThe Big Picture:  Is The Biotech Sector Heading… Read More

In this issue:The Big Picture: Biotech Sector Nears Major Decision PointIn Depth: New EBIS Pick – DYAX Corp (DYAX) – High Risk, High PotentialEBIS Portfolio Alerts: Alert: EBIS Portfolio Pricing Updates News Update: New FDA Commissioner Nominee Could Foster New Climate at AgencyThe Big Picture:  Is The Biotech Sector Heading… Read More

Our EBIS portfolio triggered some sell stops this past week.  Repligen and Bio-Rad have been removed from the STI Medical Profits portfolio.  However, due to some potential pricing issues in the Flash Crash on 8/24/15 some of the pricing may or may not have been accurate.  Thus, we are not removing Neurocrine Biosciences… Read More